FARCHEM

Far Chemical Industries Limited · Pharmaceuticals and Chemicals · Cat B

0/100

High risk

৳19.9

DSE Hexagon

Stands out for trades below its estimated worth, held back by little dividend.

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (2)

⚠ Signs of concentrated-operator price activity
⚠ Dividend sustainability at risk

Rewards (2)

✓ Trades below estimated fair value
✓ Earnings trending up

Score breakdown

Price history & performance

52-week high৳24.3

52-week low৳12.0

From 52w high-18.1%

Beta1.28

7D +2.1%

1M +8.2%

3M +17.1%

6M +41.1%

1Y +2.1%

YTD +38.2%

Shareholder returns vs DSEX

FARCHEM+0.5%

DSEX+2.4%

FARCHEM underperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility97.9%

Daily VaR (95%)-3.61%

Max drawdown (5y)-61.7%

Correlation to market0.55

More volatile than most DSE stocks — larger swings both ways. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)58.1

MACDbullish

Bollingerinside bands (+1.0σ)

Price cycle (Wyckoff)

Health trendstable

Flow pressureaccumulation

Valuation

Fair value ()

Upside—

Dividend yield+0.50%

Fundamental verdictAT-RISK

Confidence—

Ownership

Institutional holding32.08%

Foreign holding0.0%

Free float35.29%

Sponsor, institutional, foreign and public holdings from the latest disclosed shareholding pattern. Descriptive only.

Share structure

Authorized capital৳3,000mn

Paid-up capital৳1,530.97mn

Face value৳10

Market lot1

Outstanding shares153,097,333

Last AGM24-12-2025

Fiscal year end30-Jun

Reserve & surplus (ex-OCI)৳3,447.8mn

Other comprehensive income৳0mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E

Jul 14, 2026 — —

Jul 13, 2026 — —

Jul 12, 2026 — —

Jul 9, 2026 — —

Jul 8, 2026 — —

Jul 7, 2026 — —

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

20241%

20211%

20201%

20165%

Earnings & NAV

YearEPSNAVDividend

2025 0.09 32.52 0%

2024 0.2 32.53 1%

2023 -1.12 10.98 0%

2022 -0.39 12.1 0%

Quarterly EPS — FY2026

Q10.05

Q2-1.85

Half-year-1.8

Q3-1.46

Nine-month-3.26

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳20.1

৳21

৳21.8

৳22.6

Support

৳19.8

৳19

৳18.4

৳17.8

Historical bounce zones

Aug 13, 2025: ৳20.7→৳24.3 +17%

Oct 16, 2025: ৳18→৳21.8 +21%

Nov 16, 2025: ৳11.6→৳15.6 +34%

Feb 1, 2026: ৳12.9→৳15.8 +22%

Mar 8, 2026: ৳13→৳17.8 +37%

Apr 6, 2026: ৳15.1→৳18.3 +21%

May 3, 2026: ৳14.1→৳17 +21%

May 6, 2026: ৳15.6→৳21.2 +36%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

ScripScorePriceUpsideYield

IBNSINAThe IBN SINA Pharmaceutical Industry PLC 87 ৳326.5 +12.00% +2.00%MARICOMarico Bangladesh Limited 87 ৳2,732.4 +24.00% +2.20%SQURPHARMASquare Pharmaceuticals PLC. 85 ৳221.4 +120.00% +5.40%ACMELABThe ACME Laboratories Limited 79 ৳86.9 +138.00% +4.10%BXPHARMABeximco Pharmaceuticals PLC. 78 ৳153.2 +54.00% +2.60%RENATARenata PLC 64 ৳464.3 -25.00% +1.20%

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 40% vs 40% market avg Typical move: -4% / -0.7% / 3.9%

30-day 41% vs 42% market avg Typical move: -6.7% / -0.7% / 7.3%

Signals: Bearish Harami

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readAVOID (dormant/dirty)

Reference stopn/a

Reference target—

Timing notestay out

strong artificial activity (score 342); speculative profile — not core-quality. Phase: DORMANT (19% >200-MA, flow ACC) -> watch. ⚠ PAPER-PROFIT — reports profit but NEGATIVE cash flow (accrual red flag; earnings not real cash). [fundamentals AT-RISK (dividend cut risk), payout 111.0%, yield 0.5%]